FDA erred on women’s libido drug; don’t reward Palatin Technologies

FDA erred on women’s libido drug; don’t reward Palatin Technologies

STAT Plus: The FDA erred in approving new women’s libido drug; don’t reward Palatin Technologies

By ADAM FEUERSTEIN

In the clinical trials, there was no difference in the number of sexually satisfying events between the drug and placebo.

READ MORE